Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/30/2025

Management of Co‑administration of Tirzepatide (Mounjaro) and Teprotumumab (Tepezza)

Hyperglycemia Risk and Monitoring

Gastrointestinal Adverse‑Effect Overlap

Muscle‑Spasm Overlap

Baseline Assessment Prior to Combined Therapy

Ongoing Monitoring During Concurrent Therapy

Dose‑Adjustment Recommendations

Clinical Pitfalls to Avoid